Cargando…

Serum MIG6 concentration is increased by cholesterol-lowering treatment in patients with type 2 diabetes mellitus and hypercholesterolemia

OBJECTIVE: The protein encoded by mitogen-inducible gene 6 (MIG6) plays an essential role in the regulation of cholesterol homeostasis and bile acid synthesis in mice. However, the physiological functions of MIG6 remain poorly understood in humans. Therefore, we aimed to evaluate the relationship be...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Jun Choul, Kim, Ji Min, Joung, Kyong Hye, Kang, Seon Mee, Kim, Hyun Jin, Ku, Bon Jeong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8943322/
https://www.ncbi.nlm.nih.gov/pubmed/35301888
http://dx.doi.org/10.1177/03000605221085079
_version_ 1784673492941144064
author Lee, Jun Choul
Kim, Ji Min
Joung, Kyong Hye
Kang, Seon Mee
Kim, Hyun Jin
Ku, Bon Jeong
author_facet Lee, Jun Choul
Kim, Ji Min
Joung, Kyong Hye
Kang, Seon Mee
Kim, Hyun Jin
Ku, Bon Jeong
author_sort Lee, Jun Choul
collection PubMed
description OBJECTIVE: The protein encoded by mitogen-inducible gene 6 (MIG6) plays an essential role in the regulation of cholesterol homeostasis and bile acid synthesis in mice. However, the physiological functions of MIG6 remain poorly understood in humans. Therefore, we aimed to evaluate the relationship between the serum MIG6 concentration and low-density lipoprotein (LDL)-cholesterol in patients undergoing cholesterol-lowering treatment. METHODS: We performed a non-randomized, prospective controlled trial. In total, 63 patients with type 2 diabetes and hypercholesterolemia were treated using either rosuvastatin monotherapy or rosuvastatin/ezetimibe combination therapy for 12 weeks. We then compared their serum lipid and MIG6 concentrations before and after treatment. RESULTS: The serum LDL-cholesterol concentration of the participants significantly decreased and the concentration of MIG6 significantly increased during treatment. In addition, higher pre-treatment serum concentrations of MIG6 were associated with larger reductions in LDL-cholesterol, regardless of the therapeutic agent used. CONCLUSIONS: Serum MIG6 concentration significantly increases alongside the reduction in LDL-cholesterol achieved using cholesterol-lowering therapies in patients with diabetes and hypercholesterolemia. This is the first study to provide evidence that MIG6 may be involved in human cholesterol metabolism. CRIS registration number: KCT0003477. https://cris.nih.go.kr.
format Online
Article
Text
id pubmed-8943322
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-89433222022-03-25 Serum MIG6 concentration is increased by cholesterol-lowering treatment in patients with type 2 diabetes mellitus and hypercholesterolemia Lee, Jun Choul Kim, Ji Min Joung, Kyong Hye Kang, Seon Mee Kim, Hyun Jin Ku, Bon Jeong J Int Med Res Prospective Clinical Research Report OBJECTIVE: The protein encoded by mitogen-inducible gene 6 (MIG6) plays an essential role in the regulation of cholesterol homeostasis and bile acid synthesis in mice. However, the physiological functions of MIG6 remain poorly understood in humans. Therefore, we aimed to evaluate the relationship between the serum MIG6 concentration and low-density lipoprotein (LDL)-cholesterol in patients undergoing cholesterol-lowering treatment. METHODS: We performed a non-randomized, prospective controlled trial. In total, 63 patients with type 2 diabetes and hypercholesterolemia were treated using either rosuvastatin monotherapy or rosuvastatin/ezetimibe combination therapy for 12 weeks. We then compared their serum lipid and MIG6 concentrations before and after treatment. RESULTS: The serum LDL-cholesterol concentration of the participants significantly decreased and the concentration of MIG6 significantly increased during treatment. In addition, higher pre-treatment serum concentrations of MIG6 were associated with larger reductions in LDL-cholesterol, regardless of the therapeutic agent used. CONCLUSIONS: Serum MIG6 concentration significantly increases alongside the reduction in LDL-cholesterol achieved using cholesterol-lowering therapies in patients with diabetes and hypercholesterolemia. This is the first study to provide evidence that MIG6 may be involved in human cholesterol metabolism. CRIS registration number: KCT0003477. https://cris.nih.go.kr. SAGE Publications 2022-03-18 /pmc/articles/PMC8943322/ /pubmed/35301888 http://dx.doi.org/10.1177/03000605221085079 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by-nc/4.0/Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Prospective Clinical Research Report
Lee, Jun Choul
Kim, Ji Min
Joung, Kyong Hye
Kang, Seon Mee
Kim, Hyun Jin
Ku, Bon Jeong
Serum MIG6 concentration is increased by cholesterol-lowering treatment in patients with type 2 diabetes mellitus and hypercholesterolemia
title Serum MIG6 concentration is increased by cholesterol-lowering treatment in patients with type 2 diabetes mellitus and hypercholesterolemia
title_full Serum MIG6 concentration is increased by cholesterol-lowering treatment in patients with type 2 diabetes mellitus and hypercholesterolemia
title_fullStr Serum MIG6 concentration is increased by cholesterol-lowering treatment in patients with type 2 diabetes mellitus and hypercholesterolemia
title_full_unstemmed Serum MIG6 concentration is increased by cholesterol-lowering treatment in patients with type 2 diabetes mellitus and hypercholesterolemia
title_short Serum MIG6 concentration is increased by cholesterol-lowering treatment in patients with type 2 diabetes mellitus and hypercholesterolemia
title_sort serum mig6 concentration is increased by cholesterol-lowering treatment in patients with type 2 diabetes mellitus and hypercholesterolemia
topic Prospective Clinical Research Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8943322/
https://www.ncbi.nlm.nih.gov/pubmed/35301888
http://dx.doi.org/10.1177/03000605221085079
work_keys_str_mv AT leejunchoul serummig6concentrationisincreasedbycholesterolloweringtreatmentinpatientswithtype2diabetesmellitusandhypercholesterolemia
AT kimjimin serummig6concentrationisincreasedbycholesterolloweringtreatmentinpatientswithtype2diabetesmellitusandhypercholesterolemia
AT joungkyonghye serummig6concentrationisincreasedbycholesterolloweringtreatmentinpatientswithtype2diabetesmellitusandhypercholesterolemia
AT kangseonmee serummig6concentrationisincreasedbycholesterolloweringtreatmentinpatientswithtype2diabetesmellitusandhypercholesterolemia
AT kimhyunjin serummig6concentrationisincreasedbycholesterolloweringtreatmentinpatientswithtype2diabetesmellitusandhypercholesterolemia
AT kubonjeong serummig6concentrationisincreasedbycholesterolloweringtreatmentinpatientswithtype2diabetesmellitusandhypercholesterolemia